Register for email alerts and news feeds:
This journal | BMJ Group
rss
The most recent version of this article was published on 1 October 2007

Ann Rheum Dis. Published Online First: 7 March 2007. doi:10.1136/ard.2006.068650
Copyright © 2007 BMJ Publishing Group Ltd & European League Against Rheumatism.

Extended Report

Non-steroidal anti-inflammatory drugs and myocardial infarctions: Comparative systematic review of evidence from observational studies and randomised controlled trials

P A Scott 1, G H Kingsley 2, C M Smith 2, E H Choy 2 and D L Scott 2*

1 Portsmouth Hospitals NHS Trust, United Kingdom
2 Kings College London, United Kingdom

* To whom correspondence should be addressed. E-mail: david.l.scott{at}kcl.ac.uk.

Accepted 18 February 2007


Abstract

Objective: Determining the comparative risk of myocardial infarctions (MIs) with COXIBs (Cox-2 specific NSAIDs) and traditional non-steroidal anti-inflammatory drugs (NSAIDs).

Design: Systematic reviews (SRs) examined MI risks in case-control and cohort studies and randomised controlled trials (RCTs) in colonic adenomas and arthritis.

Data sources: MEDLINE, EMBASE, and CINAHL (1998- 2006) and published bibliographies.

Review Methods: We evaluated studies in English of suitable size from which crude data about MIs could be extracted.

Results: 14 case-control studies (74,673 MI patients, 368,968 controls) showed no significant association of NSAIDs with MIs in a random effects model (OR 1.17; 95% CI 0.99, 1.37) and a small risk in a fixed effects model (OR 1.32, 95% CI 1.29, 1.35). Sensitivity analyses showed higher risks in large, European studies involving matched controls. 6 cohort studies (387,983 patient years, 1,120,812 control years) showed no significant risk of MIs with NSAIDs (RR 1.03; 95% CI 1.00, 1.07); risks were higher with rofecoxib (RR 1.25; 95%CI 1.17, 1.34) but not other NSAIDs. 4 RCTs of NSAIDs in colonic adenomas (6000 patients) showed increased MI risks with NSAIDs (RR 2.68: 95% CI 1.43, 5.01). 14 RCTs in arthritis (45,425 patients) showed more MIs with COXIBs (Peto OR 1.6; 95% CI 1.1, 2.4), but fewer serious upper gastrointestinal events (Peto OR 0.40; 95% CI 0.31, 0.53).

Conclusion: Overall risks of MIs with NSAIDs and COXIBs were small; only rofecoxib showed increased MI risks in all studies. Although there was an increased MI risk in COXIBs compared to NSAIDs the incidence of serious upper gastrointestinal toxicity was reduced.

Keywords: adverse events, coxibs, myocardial infarctions, NSAIDs, systematic review


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This article has been cited by other articles:

  • Scott, P. A, Kingsley, G. H., Scott, D. L (2008). Non-steroidal anti-inflammatory drugs and cardiac failure: meta-analyses of observational studies and randomised controlled trials. Eur J Heart Fail 10: 1102-1107 [Abstract] [Full Text]  

This Article

Services
Citing Articles
Google Scholar
PubMed
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

BMJ Careers - Latest Rheumatology Jobs

Rheumatology Jobs